A prospective, non-interventional, observational study of presentation, treatment patterns and outcomes in Atypical Hemolytic Uremic Syndrome patients

Trial Identifier: D7413R00001
Sponsor: AstraZeneca
NCTID:: NCT06099236
Start Date: January 2024
Primary Completion Date: June 2028
Study Completion Date: June 2028

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Trial Locations

Country Location
China Beijing, China
China Changsha, China
China Chengdu, China
China Chongqing, China
China Fuzhou, China
China Guangzhou, China
China Jinan, China
China Nanjing, China
China Qingdao, China
China Shanghai, China
China Shenzhen, China
China Taiyuan, China
China Tianjin, China
China Wuhan, China
China Xian, China
China Zhengzhou, China
China, Guangdong Guangzhou, Guangdong, China
China, Guangxi Nanning, Guangxi, China
China, Heibei Shijiazhuang, Heibei, China
China, Sichuan Luzhou, Sichuan, China